UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
September 30, 2019
Commission File Number: 001 - 38178
Zealand Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Sydmarken 11
2860 Søborg (Copenhagen)
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release (company announcement) of Zealand Pharma A/S or the Company, dated September 30, 2019, confirming the total number of shares and voting rights in Zealand Pharma up to and including September 30, 2019.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Zealand Pharma A/S | ||
|
| ||
|
By: |
/s/ Ivan M. Møller | |
|
|
Name: |
Ivan M. Møller |
|
|
Title: |
Interim Chief Financial Officer |
Date: September 30, 2019
Company announcement No. 36 / 2019
Total number of shares and voting rights in Zealand Pharma at September 30, 2019
Copenhagen, September 30, 2019 Zealand Pharma A/S (Zealand) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers Disclosure Obligations, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement No. 33/2019 of September 11, 2019, Zealand announced an increase in share capital relating to the completion of a private placement and directed issue of new shares, and in No. 34/2019 of September 13, 2019, Zealand announced an increase in its share capital relating to the exercise of employee warrants. Following these announcements, the table below lists the total number of shares and voting rights in Zealand at September 30, 2019:
Date |
|
Number of shares |
|
Share capital |
|
Number of voting |
|
September 30, 2019 |
|
35,865,461 |
|
35,865,461 |
|
35,865,461 |
|
For further information, please contact:
Emmanuel Dulac, President and Chief Executive Officer
Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com
Lani Pollworth Morvan, Investor Relations and Communication
Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (Zealand) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealands current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealands portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
Zealand is based in Copenhagen (Søborg), Denmark. For further information about the companys business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.